Details of issuance or disposal
Monthly exercise status of Series 31 warrants issued through a third-party allotment (with exercise price adjustment clause)
Shares delivered during the month: 308,600 shares (new shares: 308,600; treasury shares transferred: 0)
The lower thin line represents the existing number of shares to which these shares will be added.
Exercise ratio subject to exercise restrictions: 1.6% (①308,600 shares / ②19,494,600 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of Series 31 warrants issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Shares delivered during the month: 308,600 shares (new shares: 308,600; treasury shares transferred: 0) |
| Intended allottee | Cantor Fitzgerald Europe (issued on 19 November 2025) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 1.6% (①308,600 shares / ②19,494,600 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 20,004,600 shares (as of the end of the month preceding the month under review) → 20,313,200 shares (as of the end of the relevant month, including the 308,600 new shares delivered during the month) |
| Exercise price | With exercise price adjustment clause. The exercise prices during the month were ¥72.0 and ¥72.9 (¥78.3 from 2 to 12 March). Floor: Not disclosed |
| Number of Stock Acquisition Rights | Total warrants issued: 129,350. Warrants exercised during the month: 3,086. Unexercised warrants as of the end of the preceding month: 124,250; as of the end of the month: 121,164 |
| Reason for acquisition without consideration | The company plans to acquire all remaining warrants as of 7 April 2026 and cancel all of them immediately after acquisition |
| Most recent equity financing | Timing 19 November 2025 / Type Issuance through a third-party allotment of Series 31 warrants (with exercise price adjustment clause) and Series 32 warrants / Amount Not disclosed |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the Series 31 warrants in March 2026. The company also explained that it plans to acquire all remaining Series 31 and Series 32 warrants as of 7 April 2026 and cancel them immediately after acquisition.